Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.82 |
| ▸ | EGLN1 | Q9GZT9 | 4/20 | 0.82 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.82 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.82 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.57 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | SLC13A3 | Q8WWT9 | 1/20 | 0.56 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | KDM5C | P41229 | 3/20 | 0.50 |
| ▸ | PHF8 | Q9UPP1 | 3/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.50 |
| ▸ | KDM6B | O15054 | 2/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL9189068 | 0.95 | LMNA (0.90) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL5738709 | 0.95 | LMNA (0.90) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL468701 | 0.95 | — | — | |
| Succinic Acid SCHEMBL140347 | 0.95 | LMNA (0.90) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL9189067 | 0.95 | LMNA (0.90) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL140348 | 0.95 | — | — | |
| Succinic Acid SCHEMBL31369063 | 0.95 | LMNA (0.90) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL14834482 | 0.95 | LMNA (0.90) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL468678 | 0.92 | LMNA (0.69) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 | |
| Succinic Acid SCHEMBL7096341 | 0.91 | LMNA (0.82) | LMNAEGLN1ALKBH5SUCNR1SLC22A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3083978-A1 | MEDIA FOR CELL CULTURE | Essential Pharmaceuticals, LLC (US) | 2016-10-26 | — | — | EP | claimed |
| CN-106062205-A | Cell culture medium | 基本药品有限责任公司 | 2016-10-26 | — | — | CN | claimed |
| US-20150329830-A1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (GB) | 2015-11-19 | — | — | US | claimed |
| WO-2015095651-A1 | MEDIA FOR CELL CULTURE | ESSENTIAL PHARMACEUTICALS, LLC (US) | 2015-06-25 | — | — | WO | claimed |
| EP-2776558-A1 | KIT COMPRISING SERUM REPLACEMENT AND LABILE FACTORS | Essential Pharmaceuticals, LLC (US) | 2014-09-17 | — | — | EP | claimed |
| CN-103958665-A | Kit comprising a serum replacement and a labile factor | ESSENTIAL PHARMACEUTICALS LLC | 2014-07-30 | — | — | CN | claimed |
| US-20130183714-A1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | MEDIMMUNE LIMITED (GB) | 2013-07-18 | — | — | US | claimed |
| US-20130130373-A1 | Kit Comprising Serum Replacement and Labile Factors | ESSENTIAL PHARMACEUTICALS, LLC (US) | 2013-05-23 | — | — | US | claimed |
| WO-2013071151-A1 | KIT COMPRISING SERUM REPLACEMENT AND LABILE FACTORS | ESSENTIAL PHARMACEUTICALS, LLC (US) | 2013-05-16 | — | — | WO | claimed |
| US-8361797-B2 | Myeloma cell culture in transferrin-free low iron medium | MEDIMMUNE LIMITED (GB) | 2013-01-29 | — | — | US | claimed |
| EP-1651754-B1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | CAMBRIDGE ANTIBODY TECH (GB) | 2007-04-11 | — | — | EP | claimed |
| US-20070031964-A1 | Myeloma cell culture in transferrin-free low iron medium | MEDIMMUNE LIMITED (GB) | 2007-02-08 | — | — | US | claimed |
| JP-2007501606-A | — | — | 2007-02-01 | — | — | JP | claimed |
| CN-1867665-A | Myeloma cell culture in transferrin-free low iron medium | CAMBRIDGE ANTIBODY TECH (GB) | 2006-11-22 | — | — | CN | claimed |
| EP-1651754-A1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | Cambridge Antibody Technology Limited (GB) | 2006-05-03 | — | — | EP | claimed |
| WO-2005014800-A1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (GB) | 2005-02-17 | — | — | WO | claimed |
| CN-115943157-A | Use of plant protein homologues in culture media | 耶路撒冷希伯来大学伊森姆研究发展公司 | 2023-04-07 | — | — | CN | disclosed |
| US-20230091231-A1 | UTILIZATION OF PLANT PROTEIN HOMOLOGUES IN CULTURE MEDIA | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2023-03-23 | — | — | US | disclosed |
| EP-1651754-A1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | Cambridge Antibody Technology Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005014800-A1 | MYELOMA CELL CULTURE IN TRANSFERRIN-FREE LOW IRON MEDIUM | CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |